{
    "title": "Rivers",
    "link": "https://www.thebottomline.org.uk/summaries/icm/rivers/",
    "summary": "In adults with severe sepsis or septic shock, does the use of early goal-directed therapy (EGDT) reduce the mortality?",
    "full_content": "\nTweet\nEarly goal-directed therapy in the treatment of severe sepsis and septic shock\nRivers. NEJM 2001; 345:1368-1377. doi:10.1056/NEJMoa010307\nClinical Question\n\nIn adults with severe sepsis or septic shock, does the use of early goal-directed therapy (EGDT) reduce the mortality?\n\nDesign\n\nRandomised controlled trial\nComputer-generated blocks of 2 to 8\nConcealed allocation\nNo blinding of clinicians, study personnel or patients\nPower calculation: sample size of 260 required with 80% power and 0.05 alpha error rate to detect absolute reduction in mortality of 15% (expected baseline not specified)\nIntention-to-treat analysis\n\nSetting\n\nSingle academic tertiary hospital in Detroit, USA\nMarch 1997 to March 2000\n\nPopulation\n\nInclusion: Severe sepsis or septic shock\n\n\u2265 2 SIRS features, and either\nsystolic BP \u2264 90 mmHg after crystalloid fluid of 20 to 30 ml/kg over 30 minutes, or\nblood lactate \u2265 4 mmol/l\n\n\nExclusion: age under 18 years; pregnancy; other acute neurological, cardiac, gastrointestinal or respiratory pathology; contraindications to central catheterisation; uncured cancer; immunosupression; limitations defined for active care\n268 randomised with 236 completing study\n\nIntervention\n\nEarly goal-directed therapy for 6 hours\n\nRemained in ED for 6 hours and protocolised therapy managed by an emergency physician, two residents and three nurses\nOxygen \u00b1 intubation and mechanical ventilation\nCentral venous and arterial catheterisation\nCentral venous catheter (Edwards Lifesciences) capable of measuring continuous ScvO2\u00a0\n500 ml fluid boluses until CVP 8\u201312 mmHg\nVasopressors or vasodilators until MAP 65\u201390 mmHg\nIf ScvO2 < 70%\n\nTransfused red cells until haematocrit \u2265 30%\nIf still\u00a0ScvO2\u00a0< 70%\n\nDobutamine 2.5\u201320 \u00b5g/kg/min until\u00a0ScvO2\u00a0> 70%\nDobutamine limited or reduced if MAP < 65 mmHg or pulse > 120 /min\n\n\n\n\n\n\n\nControl\n\nUsual care for 6 hours without protocol\n\nTreatment at the discretion of the clinician and patient admitted to ICU as soon as possible after consult and lines inserted\nOxygen \u00b1 intubation and mechanical ventilation\nCentral venous and arterial catheterisation\nTargets defined but without treatment algorithm:\n\nCVP\u00a0\u2265 8\u201312 mmHg\nMAP\u00a0\u2265 65 mmHg\nUrine output\u00a0\u2265 0.5 ml/kg/hr\n\n\n\n\n\nOutcome\n\nPrimary outcome: in-hospital mortality was statistically and clinically significantly better in the EGDT intervention group compared to the usual care control group.\n\n30.5% vs 46.5% p = 0.009\n\n\nSecondary outcome: subgroup analyses all favoured EDGT\n\nseverity of sepsis\n28-day and 60-day mortality\ncause of in-hospital death (sudden cardiovascular collapse and multi-organ failure)\n\n\nTertiary data collection:\n\nThe EGDT group received more fluid over the early 6-hour period but there was no difference in total fluid over 72 hours\nMore red-cell transfusions were given to the EGDT group\nEarly inotropic use was more prevalent in the EGDT group (not statistically different over complete 72-hour period)\nVasopressor use was more prevalent in the usual care group\nIntubation and ventilation was more prevalent in the usual care group\n\n\n\n\n\nPrimary Outcome\n\n\nMeasure\nEGDT\nUsual Care\nARR\n95% CI\np\nNNT\n\n\n\n\nIn-hospital mortality\n29.2%\n44.4%\n15.13%\n3.62 to 26.64%\n0.0150\n7\n\n\n\n\nARR = absolute risk reduction; CI = confidence interval; p = p value; NNT = number needed-to-treat\nFishers\u2019 exact test performed on reported in-hopsital mortality. This is different to Kaplan-Meier survival estimates reported in the orginal paper.\n\n\n\n\nAuthors\u2019 Conclusions\n\n\u201cgoal-directed therapy provided at the earliest stages of severe sepsis and septic shock\u2026 has significant short-term and long-term benefits.\u201d\n\nStrengths\n\nAdequate trial design for the clinical question\n90% completed the study \u2013 a drop-out / lost-follow-up rate that is well below the primary outcome rate\n\nWeaknesses\n\nSingle centre study\nIntervention was a bundle of care, and individual components cannot be investigated separately\nUsual care control group had a higher than average mortality rate\nIn-hospital mortality as an outcome measure has its limitations, as some patients will go to institutions or home to die soon after\nLead author is a paid consultant for manufacturer of ScvO2-measuring central catheter, and has registered \u201cearly goal-directed therapy\u201d and \u201cEGDT\u201d as his trademarks!\n\n\nThe Bottom Line\n\nUntil ProCESS, ARISE and ProMISe, Rivers\u2019 trial represented the best evidence for EGDT and demonstrated a strong benefit.\nConcerns and criticism by clinicians has led to modified but widespread adoption of the \u2018bundle\u2019 of care in severe sepsis and septic shock.\nUntil individual elements are tested, the specific goals are not unreasonable goals to target, although the algorithm is perhaps less robust.\n\n\n\nExternal Links\n\n[article pdf]\u00a0Early goal-directed therapy in the treatment of severe sepsis and septic shock by Rivers et al\n[podcast] Early Goal Directed Therapy by @EmCrit\n[further reading]\u00a0Infographical comparison of Rivers vs ProCESS by Cheetah Medical (commercial manufacturer of haemodynamic monitors)\n[further reading] A brief history of goal directed therapy by Otero (Am Col Em Physicians)\n\nMetadata\nSummary author: @DuncanChambler\nSummary date: 3 October 2014\nPeer-review editor:\u00a0@stevemathieu75\n\n\n"
}